The 10.7% Bone-Density Change That Kept Akatsuka Awake
After seven months of consistent URAH use alongside ongoing care, Mr. Maejima's recorded bone-density measurement changed from 2.71 mmAI to 3.00 mmAI. For Akatsuka, the professional following his progress, the result was impossible to forget.
Two Readings, Seven Months Apart
Mr. Maejima was receiving care at Tezuka Surgery Clinic in Japan when his initial bone-density measurement was recorded at 2.71 mmAI.
Bone-related changes are difficult to judge by feeling alone. What mattered in this case was the opportunity to follow his progress over time and compare his original measurement with a later reading.
As part of his ongoing bone-health routine, Mr. Maejima began applying URAH consistently. He continued using it alongside his existing care over the following seven months.
The Follow-Up Reading: 3.00 mmAI
At the seven-month follow-up, Mr. Maejima's recorded measurement was 3.00 mmAI — a difference of approximately 10.7% between the two readings.
| Measurement | |
|---|---|
| Initial Reading | 2.71 mmAI |
| 7-Month Follow-Up | 3.00 mmAI |
| Recorded Difference | Approximately 10.7% |
In Mr. Maejima's Words
"Before this, I was always conscious of my bone health. It was difficult knowing that there was a problem I could not see or feel changing from one day to the next. What helped me most was having something simple I could apply consistently as part of my routine.
I did not expect an overnight change. I simply continued using URAH and kept attending my follow-up care. When I was shown that the measurement had changed from 2.71 mmAI to 3.00 mmAI after seven months, I was genuinely surprised.
For me, the biggest difference was not only the number. Seeing that follow-up reading gave me encouragement. It made me feel that the consistency had been worthwhile and gave me greater confidence to continue looking after my bone health.
I understand that this is my individual experience and that everyone's circumstances are different. But after seven months of maintaining the routine, seeing something measurable meant a great deal to me."
— Mr. Maejima, URAH customer
The Result Akatsuka Could Not Stop Thinking About
For Akatsuka, the professional documenting Mr. Maejima's progress, the follow-up reading was not merely another number on a clinic record. It stayed with him long after the day had ended.
"I couldn't sleep last night. I kept thinking about the potential this product has — not just for my patient, but for the world."
— Akatsuka, reflecting on the follow-up result
Why the Change Felt So Significant
In describing his reaction, Akatsuka compared Mr. Maejima's change with reports he had seen involving NASA and JAXA astronauts using bisphosphonates to manage bone loss in space.
He referred to annual improvements of approximately 1–5% in that context. Against that personal point of reference, seeing a 10.7% difference between Mr. Maejima's readings over seven months felt remarkable to him.
This was Akatsuka's own comparison — and the reason the follow-up result affected him so deeply.
"This level of increase is unprecedented in my clinical experience. I've monitored many patients and studied numerous treatments, but nothing compares to what we witnessed here."
— Akatsuka
A Routine Built Around Consistency
Mr. Maejima did not use URAH as an instant remedy. He incorporated the topical cream into his ongoing routine and continued applying it consistently over seven months.
Bone-related changes require time and professional monitoring; they cannot be judged by an immediate warming or cooling sensation. URAH's micellar platform is designed to help glucosamine cross the skin barrier around the application site before absorbed glucosamine enters circulation.
Starts where you apply it. Circulation carries support further.
Why We Chose to Share This Experience
This is not a story about an overnight transformation. It is about maintaining a routine long enough to return for a follow-up measurement. For Mr. Maejima, the new reading brought encouragement and greater confidence to continue looking after his bone health. For Akatsuka, it became the result that kept him awake, thinking about what might be possible.
2.71 mmAI before. 3.00 mmAI seven months later. Approximately 10.7% between the readings.
About This Experience
This account describes one individual's experience and two reported measurements. It is not a controlled clinical study and does not establish that URAH caused the recorded change. Bone measurements may be influenced by medical care, nutrition, activity, health status and measurement conditions. Akatsuka's NASA and JAXA comparison is his personal interpretation; spaceflight research involves different conditions and methods and does not show that URAH is equivalent or superior to bisphosphonate treatment. URAH is a complementary daily support routine. It does not diagnose, treat or cure osteoporosis or replace monitoring and clinician-directed care. Individual experiences vary.
